Mucopolysaccharidosis type I (MPS IH; Hurler syndrome) is a rare genetic disorder that is caused by mutations in the α-L-iduronidase (IDUA) gene, resulting in the deficiency of IDUA enzyme activity and intra-cellular accumulation of glycosaminoglycans. A characteristic skeletal phenotype is one of the many clinical manifestations in Hurler disease. Since the mechanism(s) underlying these skeletal defects are not completely understood, and bone and cartilage are mesenchymal lineages, we focused on the characterization of mesenchymal cells isolated from the bone marrow (BM) of 5 Hurler patients. IDUA-mutated BM stromal cells (BMSC) derived from MPS IH patients exhibited decreased IDUA activity, consistent with the disease genotype. The expansion rate, phenotype, telomerase activity, and differentiation capacity toward adipocytes, osteoblasts, chondrocytes, and smooth muscle cells in vitro of the MPS I BMSC lines were similar to those of BMSC from age-matched normal control donors. MPS I BMSC also had a similar in vivo osteogenic capacity as normal BMSC. However, MPS I BMSC displayed an increased capacity to support osteoclastogenesis, which may correlate with the up-regulation of the RANKL/RANK/OPG molecular pathway in MPS I BMSC compared with normal BMSC.
Get full access to this article
View all access options for this article.
References
1.
NeufeldEF, MuenzerJ. 2001. The mucopolysaccharidoses. The Metabolic and Molecular Bases of Inherited Disease. ScriverCR, BeaudetAL, SlyWS, ValleD, ChildsB, KinzlerKW. Mc Graw-Hill: New York, 3427–3436.
2.
ClarkeLA. 2008. The mucopolysaccharidoses: a success of molecular medicine. Expert Rev Mol Med, 10:e1.
3.
AldenhovenM, SakkersRJ, BoelensJ, de KoningTJ, WulffraatNM. 2009. Musculoskeletal manifestations of lysosomal storage disorders. Ann Rheum Dis, 68:1659–1665.
4.
MuenzerJ, FisherA. 2004. Advances in the treatment of mucopolysaccharidosis type I. N Engl J Med, 350:1932–1934.
5.
AldenhovenM, BoelensJJ, de KoningTJ. 2008. The clinical outcome of Hurler syndrome after stem cell transplantation. Biol Blood Marrow Transplant, 14:485–498.
6.
WeissteinJS, DelgadoE, SteinbachLS, HartK, PackmanS. 2004. Musculoskeletal manifestations of Hurler syndrome: long-term follow-up after bone marrow transplantation. J Pediatr Orthop, 24:97–101.
7.
FieldRE, BuchananJA, CopplemansMG, AichrothPM. 1994. Bone-marrow transplantation in Hurler's syndrome. Effect on skeletal development. J Bone Joint Surg Br, 76:975–981.
8.
RussellC, HendsonG, JevonG, MatlockT, YuJ, AklujkarM, NgKY, ClarkeLA. 1998. Murine MPS I: insights into the pathogenesis of Hurler syndrome. Clin Genet, 53:349–361.
9.
WilsonS, HashamiyanS, ClarkeL, SaftigP, MortJ, DejicaVM, BrommeD. 2009. Glycosaminoglycan-mediated loss of cathepsin K collagenolytic activity in MPS I contributes to osteoclast and growth plate abnormalities. Am J Pathol, 175:2053–2062.
10.
SimonaroCM, D'AngeloM, HeX, EliyahuE, ShtraizentN, HaskinsME, SchuchmanEH. 2008. Mechanism of glycosaminoglycan-mediated bone and joint disease: implications for the mucopolysaccharidoses and other connective tissue diseases. Am J Pathol, 172:112–122.
11.
SimonaroCM, GeY, EliyahuE, HeX, JepsenKJ, SchuchmanEH. 2010. Involvement of the Toll-like receptor 4 pathway and use of TNF-alpha antagonists for treatment of the mucopolysaccharidoses. Proc Natl Acad Sci, 107:222–227.
BiancoP, RobeyP. 1999. Diseases of bone and the stromal cell lineage. J Bone Miner Res, 14:336–341.
14.
RobeyPG, BiancoP. 1999. The role of osteogenic cells in the pathophysiology of Paget's disease. J Bone Miner Res, 14,Suppl. 2:9–16.
15.
StenderupK, JustesenJ, EriksenEF, RattanSI, KassemM. 2001. Number and proliferative capacity of osteogenic stem cells are maintained during aging and in patients with osteoporosis. J Bone Miner Res, 16:1120–1129.
16.
OreffoRO, BennettA, CarrAJ, TriffittJT. 1998. Patients with primary osteoarthritis show no change with ageing in the number of osteogenic precursors. Scand J Rheumatol, 27:415–424.
17.
Dalle CarbonareL, ValentiMT, ZanattaM, DonatelliL, Lo CascioV. 2009. Circulating mesenchymal stem cells with abnormal osteogenic differentiation in patients with osteoporosis. Arthritis Rheum, 60:3356–3365.
18.
Meirelles LdaS, NardiNB. 2003. Murine marrow-derived mesenchymal stem cell: isolation, in vitro expansion, and characterization. Br J Haematol, 123:702–711.
19.
BoyleWJ, SimonetWS, LaceyDL. 2003. Osteoclast differentiation and activation. Nature, 423:337–342.
20.
WadaT, NakashimaT, HiroshiN, PenningerJM. 2006. RANKL-RANK signaling in osteoclastogenesis and bone disease. Trends Mol Med, 12:17–25.
SalvadèA, BelottiD, DonzelliE, D'AmicoG, GaipaG, RenoldiG, CariniF, BaldoniM, PoglianiEMet al.2007. GMP-grade preparation of biomimetic scaffolds with osteo-differentiated autologous mesenchymal stromal cells for the treatment of alveolar bone resorption in periodontal disease. Cytotherapy, 9:427–438.
KrebsbachPH, KuznetsovSA, SatomuraK, EmmonsRV, RoweDW, RobeyPG. 1997. Bone formation in vivo: comparison of osteogenesis by transplanted mouse and human marrow stromal fibroblasts. Transplantation, 63:1059–1069.
29.
KuznetsovSA, KrebsbachPH, SatomuraK, KerrJ, RiminucciM, BenayahuD, RobeyPG. 1997. Single-colony derived strains of human marrow stromal fibroblasts form bone after transplantation in vivo. J Bone Miner Res, 12:1335–1347.
30.
SacchettiB, FunariA, MichienziS, Di CesareS, PiersantiS, SaggioI, TagliaficoE, FerrariS, RobeyPG, RiminucciM, BiancoP. 2007. Self-renewing osteoprogenitors in bone marrow sinusoids can organize a hematopoietic microenvironment. Cell, 131:324–336.
31.
DattaS, SattenGA. 2005. Rank-sum tests for clustered data. J Am Stat Ass, 100:908–915.
32.
HinekA, WilsonSE. 2000. Impaired elastogenesis in Hurler disease: dermatan sulfate accumulation linked to deficiency in elastin-binding protein and elastic fiber assembly. Am J Pathol, 156:925–938.
33.
MbalavieleG, JaiswalN, MengA, ChengL, Van Den BosC, ThiedeM. 1999. Human mesenchymal stem cells promote human osteoclast differentiation from CD34+ bone marrow hematopoietic progenitors. Endocrinology, 140:3736–3743.
34.
SilveriCP, KaplanFS, FallonMD, BayeverE, AugustCS. 1991. Hurler syndrome with special reference to histologic abnormalities of the growth plate. Clin Orthop Relat Res, 269:305–311.
35.
ClearyMA, WraithJE. 1995. The presenting features of mucopolysaccharidosis type IH (Hurler syndrome)Acta Paediatr, 84:337–339.
36.
PastoresGM. 2008. Musculoskeletal complications encountered in the lysosomal storage disorders. Best Pract Res Clin Rheumatol, 22:937–947.
37.
SimonaroCM, HaskinsME, SchuchmanEH. 2001. Articular chondrocytes from animals with a dermatan sulfate storage disease undergo a high rate of apoptosis and release nitric oxide and inflammatory cytokines: a possible mechanism underlying degenerative joint disease in the mucopolysaccharidoses. Lab Invest, 81:1319–1328.
38.
RiminucciM, SaggioI, RobeyPG, BiancoP. 2006. Fibrous dysplasia as a stem cell disease. J Bone Miner Res, 21,Suppl. 2:125–131.
39.
BiancoP, RiminucciM, GronthosS, RobeyPG. 2001. Bone marrow stromal stem cells: nature, biology, and potential applications. Stem Cells, 19:180–192.
40.
KuznetsovSA, MankaniMH, BiancoP, RobeyPG. 2009. Enumeration of the colony-forming units-fibroblast from mouse and human bone marrow in normal and pathological conditions. Stem Cell Res, 2:83–94.
41.
SimonaroCM, D'AngeloM, HaskinsME, SchuchmanEH. 2005. Joint and bone disease in mucopolysaccharidoses VI and VII: identification of new therapeutic targets and biomarkers using animal models. Pediatr Res, 57:701–707.
42.
ClarkeLA, RussellCS, PownallS, WarringtonCL, BorowskiA, DimmickJE, TooneJ, JirikFR. 1997. Murine mucopolysaccharidosis type I: targeted disruption of the murine alpha-L-iduronidase gene. Hum Mol Genet, 6:503–511.
43.
SchettG, HayerS, ZwerinaJ, RedlichK, SmolenJS. 2005. Mechanisms of Disease: the link between RANKL and arthritic bone disease. Nat Clin Pract Rheumatol, 1:47–54.
44.
RomasE, GillespieMT, MartinTJ. 2002. Involvement of receptor activator of NFkappaB ligand and tumor necrosis factor-alpha in bone destruction in rheumatoid arthritis. Bone, 30:340–346.
45.
McClungM. Role of RANKL inhibition in osteoporosis. 2007. Arthritis Res Ther, 9,Suppl. 1:S3.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
